AxoGen (NASDAQ:AXGN) Announces Earnings Results

AxoGen (NASDAQ:AXGN - Get Free Report) released its earnings results on Tuesday. The medical equipment provider reported $0.01 earnings per share for the quarter, missing analysts' consensus estimates of $0.04 by ($0.03), Zacks reports. The business had revenue of $49.41 million during the quarter, compared to analysts' expectations of $49.40 million. AxoGen had a negative return on equity of 14.91% and a negative net margin of 7.91%. AxoGen updated its FY 2025 guidance to EPS.

AxoGen Trading Up 3.0 %

Shares of NASDAQ AXGN traded up $0.58 during midday trading on Friday, reaching $20.01. 1,169,850 shares of the stock were exchanged, compared to its average volume of 542,278. The stock has a market capitalization of $880.60 million, a P/E ratio of -62.53 and a beta of 1.00. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.47 and a current ratio of 3.74. The company has a 50 day simple moving average of $17.66 and a 200 day simple moving average of $14.99. AxoGen has a twelve month low of $5.55 and a twelve month high of $21.00.

Analysts Set New Price Targets

Separately, Canaccord Genuity Group upped their target price on AxoGen from $22.00 to $26.00 and gave the company a "buy" rating in a report on Wednesday.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.